SG11201607046VA - HUMANIZED ANTI-IgE ANTIBODIES THAT CROSSLINK CD23 ON B LYMPHOCYTES BUT DO NOT SENSITIZE MAST CELLS - Google Patents
HUMANIZED ANTI-IgE ANTIBODIES THAT CROSSLINK CD23 ON B LYMPHOCYTES BUT DO NOT SENSITIZE MAST CELLSInfo
- Publication number
- SG11201607046VA SG11201607046VA SG11201607046VA SG11201607046VA SG11201607046VA SG 11201607046V A SG11201607046V A SG 11201607046VA SG 11201607046V A SG11201607046V A SG 11201607046VA SG 11201607046V A SG11201607046V A SG 11201607046VA SG 11201607046V A SG11201607046V A SG 11201607046VA
- Authority
- SG
- Singapore
- Prior art keywords
- crosslink
- lymphocytes
- mast cells
- humanized anti
- ige antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
- C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Pulmonology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Otolaryngology (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462013196P | 2014-06-17 | 2014-06-17 | |
| PCT/US2015/035981 WO2015195631A1 (en) | 2014-06-17 | 2015-06-16 | HUMANIZED ANTI-IgE ANTIBODIES THAT CROSSLINK CD23 ON B LYMPHOCYTES BUT DO NOT SENSITIZE MAST CELLS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201607046VA true SG11201607046VA (en) | 2016-10-28 |
Family
ID=54936031
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201607046VA SG11201607046VA (en) | 2014-06-17 | 2015-06-16 | HUMANIZED ANTI-IgE ANTIBODIES THAT CROSSLINK CD23 ON B LYMPHOCYTES BUT DO NOT SENSITIZE MAST CELLS |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US10047166B2 (es) |
| EP (1) | EP3157951B1 (es) |
| JP (1) | JP6397938B2 (es) |
| KR (1) | KR101892837B1 (es) |
| CN (1) | CN106573972B (es) |
| AU (1) | AU2015277379B2 (es) |
| CA (1) | CA2943588C (es) |
| DK (1) | DK3157951T3 (es) |
| ES (1) | ES2811303T3 (es) |
| MX (1) | MX371053B (es) |
| NZ (1) | NZ723520A (es) |
| PT (1) | PT3157951T (es) |
| SG (1) | SG11201607046VA (es) |
| TW (1) | TWI542598B (es) |
| WO (1) | WO2015195631A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7128191B2 (ja) * | 2017-01-06 | 2022-08-30 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 治療抗ＩｇＥ抗体並びにその方法及び組成物 |
| JPWO2020059832A1 (ja) * | 2018-09-21 | 2021-09-30 | 国立研究開発法人理化学研究所 | ＩｇＥ抗体産生Ｂ細胞の膜結合型ＩｇＥ抗体に特異的に結合する抗ＩｇＥ抗体とこれを用いたアレルギー症状の診断および治療方法 |
| CN113372450A (zh) * | 2020-03-10 | 2021-09-10 | 北京万华生物工程有限公司 | IgE嵌合性双特异性抗体制备及应用 |
| RU2760825C1 (ru) * | 2020-11-30 | 2021-11-30 | Федеральное государственное бюджетное образовательное учреждение дополнительного профессионального образования «Российская медицинская академия непрерывного профессионального образования» Министерства здравоохранения Российской Федерации | Способ лечения больных аллергическим ринитом в сочетании с хроническим риносинуситом бактериальной этиологии с использованием отечественного топического иммунокорректора |
| CN112552403A (zh) * | 2020-12-25 | 2021-03-26 | 南京英瀚斯生物科技有限公司 | 一种人源抗人CD23抗体的Fab片段、药物组合物及其应用 |
| CN112646036B (zh) * | 2021-01-21 | 2022-05-31 | 苏州百道医疗科技有限公司 | 一种抗cd23特异性单克隆抗体及其应用 |
| CN118119641A (zh) * | 2021-10-12 | 2024-05-31 | 联合生物制药股份有限公司 | Ige调节的疾病的治疗 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2012217A (en) * | 1932-06-07 | 1935-08-20 | Borson Ben | Automatic bucket tally |
| US4940782A (en) | 1987-06-08 | 1990-07-10 | G. D. Searle & Co. | Monoclonal antibodies against IgE-associated determinants, hybrid cell lines producing these antibodies, and use therefore |
| US20040049014A1 (en) * | 1988-12-28 | 2004-03-11 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US6685939B2 (en) * | 1991-08-14 | 2004-02-03 | Genentech, Inc. | Method of preventing the onset of allergic disorders |
| US6329509B1 (en) * | 1991-08-14 | 2001-12-11 | Genentech, Inc. | Anti-IgE antibodies |
| US5958708A (en) * | 1992-09-25 | 1999-09-28 | Novartis Corporation | Reshaped monoclonal antibodies against an immunoglobulin isotype |
| US6066718A (en) * | 1992-09-25 | 2000-05-23 | Novartis Corporation | Reshaped monoclonal antibodies against an immunoglobulin isotype |
| US6037453A (en) * | 1995-03-15 | 2000-03-14 | Genentech, Inc. | Immunoglobulin variants |
| US5994511A (en) * | 1997-07-02 | 1999-11-30 | Genentech, Inc. | Anti-IgE antibodies and methods of improving polypeptides |
| US6172213B1 (en) * | 1997-07-02 | 2001-01-09 | Genentech, Inc. | Anti-IgE antibodies and method of improving polypeptides |
| TWI239847B (en) * | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| BR9813365A (pt) * | 1997-12-05 | 2004-06-15 | Scripps Research Inst | Método para produção e humanização de um anticorpo monoclonal de rato |
| US20020076404A1 (en) * | 1998-01-29 | 2002-06-20 | Chang Tse Wen | Treating atopic dermatitis with IgE antagonists |
| WO2001023432A1 (fr) * | 1999-09-30 | 2001-04-05 | Kyowa Hakko Kogyo Co., Ltd. | Anticorps humain de transplantation d'une region de determination de la complementarite agissant contre le ganglioside gd3, et derives dudit anticorps |
| WO2003050531A2 (en) * | 2001-12-11 | 2003-06-19 | Algonomics N.V. | Method for displaying loops from immunoglobulin domains in different contexts |
| JP4764334B2 (ja) * | 2003-02-01 | 2011-08-31 | タノックス インコーポレーテッド | 高親和性抗ヒトＩｇＥ抗体 |
| US20050288491A1 (en) * | 2004-02-17 | 2005-12-29 | Wilson David S | Super-humanized antibodies against respiratory syncytial virus |
| PT3540062T (pt) * | 2004-11-16 | 2021-07-06 | Humanigen Inc | Permuta de cassete de região variável de imunoglobulina |
| US8080249B2 (en) * | 2005-06-30 | 2011-12-20 | Risk Glifford G | Methods to treating chronic obstructive pulmonary disease |
| SI2132230T1 (sl) * | 2007-03-22 | 2014-07-31 | Genentech, Inc. | Apoptotska protitelesa, ki veĹľejo membransko-vezan IgE |
| AU2010217100B2 (en) * | 2009-02-25 | 2014-03-27 | Academia Sinica | Anti-CepsilonmX antibodies capable of binding to human mIgE on B lymphocytes |
| WO2011146514A2 (en) * | 2010-05-17 | 2011-11-24 | The Board Of Regents Of The University Of Texas System | Rapid isolation of monoclonal antibodies from animals |
| EP2838919A4 (en) * | 2012-04-20 | 2016-03-23 | Academia Sinica | ANTIBLE ANTIBODIES BINDING TO THE TRANSITION BETWEEN CH4 AND C EPSILON MX DOMAINS |
-
2015
- 2015-06-16 AU AU2015277379A patent/AU2015277379B2/en active Active
- 2015-06-16 MX MX2016015838A patent/MX371053B/es active IP Right Grant
- 2015-06-16 JP JP2016571309A patent/JP6397938B2/ja active Active
- 2015-06-16 DK DK15810347.3T patent/DK3157951T3/da active
- 2015-06-16 PT PT158103473T patent/PT3157951T/pt unknown
- 2015-06-16 WO PCT/US2015/035981 patent/WO2015195631A1/en active Application Filing
- 2015-06-16 KR KR1020167028831A patent/KR101892837B1/ko active IP Right Grant
- 2015-06-16 CN CN201580031892.4A patent/CN106573972B/zh active Active
- 2015-06-16 ES ES15810347T patent/ES2811303T3/es active Active
- 2015-06-16 SG SG11201607046VA patent/SG11201607046VA/en unknown
- 2015-06-16 CA CA2943588A patent/CA2943588C/en active Active
- 2015-06-16 US US15/318,360 patent/US10047166B2/en active Active
- 2015-06-16 NZ NZ723520A patent/NZ723520A/en unknown
- 2015-06-16 TW TW104119331A patent/TWI542598B/zh active
- 2015-06-16 EP EP15810347.3A patent/EP3157951B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2015195631A1 (en) | 2015-12-23 |
| TWI542598B (zh) | 2016-07-21 |
| CA2943588C (en) | 2019-04-30 |
| CN106573972A (zh) | 2017-04-19 |
| US10047166B2 (en) | 2018-08-14 |
| MX2016015838A (es) | 2017-02-02 |
| DK3157951T3 (da) | 2020-08-17 |
| NZ723520A (en) | 2018-06-29 |
| KR101892837B1 (ko) | 2018-08-28 |
| PT3157951T (pt) | 2020-08-24 |
| CA2943588A1 (en) | 2015-12-23 |
| TW201600528A (zh) | 2016-01-01 |
| US20170121425A1 (en) | 2017-05-04 |
| ES2811303T3 (es) | 2021-03-11 |
| AU2015277379B2 (en) | 2017-06-29 |
| JP6397938B2 (ja) | 2018-09-26 |
| EP3157951A1 (en) | 2017-04-26 |
| KR20160131115A (ko) | 2016-11-15 |
| EP3157951B1 (en) | 2020-05-13 |
| AU2015277379A1 (en) | 2016-09-08 |
| JP2017518320A (ja) | 2017-07-06 |
| EP3157951A4 (en) | 2017-12-13 |
| CN106573972B (zh) | 2021-04-06 |
| MX371053B (es) | 2020-01-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL262144A (en) | t cell receptors | |
| ZA201806866B (en) | T cell receptors | |
| ZA202000803B (en) | Anti-ige antibodies | |
| ZA201806865B (en) | T cell receptors | |
| IL264425B1 (en) | t cell receptors against kras-g20 | |
| SG11201607046VA (en) | HUMANIZED ANTI-IgE ANTIBODIES THAT CROSSLINK CD23 ON B LYMPHOCYTES BUT DO NOT SENSITIZE MAST CELLS | |
| SG11201700687TA (en) | Anti-pd-l1 antibodies | |
| IL266208A (en) | Methods for scanning lymphocyte-b cells | |
| ZA202105220B (en) | Cell penetrating antibodies | |
| IL247285A0 (en) | Monoclonal antibodies against the Marburg virus | |
| GB201603088D0 (en) | Cell sorting | |
| GB201521284D0 (en) | Fuel cell | |
| GB201604044D0 (en) | Fuel cell | |
| PL3433270T3 (pl) | Receptory limfocytów t | |
| IL247371A0 (en) | Antibodies from individuals with increased stability | |
| PL3178929T3 (pl) | Nowe przeciwciało przeciwko ludzkiej ig(beta) | |
| GB201418266D0 (en) | Fuel cell assembly |